Acacia Subsidiary Acquires Rights to Patents in Orthopedic Technology Sector

Thu Dec 27, 2012 6:00am EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20121227:nBw275099a

NEWPORT BEACH, Calif.--(Business Wire)--
Acacia Research Corporation (Nasdaq: ACTG) announced today that a subsidiary has
acquired rights to patents in the orthopedic technology sector. 

"Acacia continues to increase the number of patent portfolios we control in the
medical device and diagnostics sectors," commented Paul Ryan, CEO. 

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation`s subsidiaries partner with inventors and patent
owners, license the patents to corporate users, and share the revenue. Acacia
Research Corporation`s subsidiaries control 250 patent portfolios, covering
technologies used in a wide variety of industries. 

Information about Acacia Research Corporation and its subsidiaries is available
at www.acaciaresearchgroup.com and www.acaciaresearch.com. 

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform Act of
1995.These statements are based upon our current expectations and speak only as
of the date hereof.Our ability to continue increasing the number of patent
portfolios in the medical device and diagnostics sectors, and our actual results
may differ materially and adversely from those expressed in any forward-looking
statements as a result of various factors and uncertainties, including the
recent economic slowdown affecting technology companies, theability to
successfully develop licensing programs and attract new business within the
medical field, rapid technological change in relevantmarkets, changes in demand
for current and future intellectual property rights, legislative, regulatory and
competitive developments addressing licensing and enforcement of patents and/or
intellectual property in general, and general economic conditions.Our Annual
Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q,
recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss
some of the important risk factors that may affect our business, results of
operations and financial condition.We undertake no obligation to revise or
update publicly any forward-looking statements for any reason.

Acacia Research Corporation
Rob Stewart
Investor Relations
Tel (949) 480-8300
Fax (949) 480-8301
or
Media Contact:
SpecOps Communications
Adam Handelsman
President & Founder
(212) 518-7721
adam@specopscomm.com



Copyright Business Wire 2012
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.